Rafael Rosell

25PUBLICATIONS
94CO-AUTHORS
ChemotherapyMolecular targetsPredictive and prognostic markersHistory of economic thoughtClimate change impacts and adaptation not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|May 25, 2026
Chemotherapy in combination with KRAS inhibitors in KRAS-mutated non-small cell lung cancer.

|Mar 05, 2026
Cetuximab co-treatment with KRAS G12C inhibitors fulzerasib and sotorasib in human KRAS G12C non-small cell lung cancer cells.

Daniel Olmo-González, Mengxin Zhou, Nuno G Oliveira

|Nov 27, 2024
Prognostic Significance of PD-L1 Expression on Circulating Myeloid-Derived Suppressor Cells in NSCLC Patients Treated with Anti-PD-1/PD-L1 Checkpoint Inhibitors.

Roser Salvia, Laura G Rico, Teresa Morán

|Sep 28, 2024
Novel DNA Repair Inhibitors Targeting XPG to Enhance Cisplatin Therapy in Non-Small Cell Lung Cancer: Insights from In Silico and Cell-Based Studies.

Rita Manguinhas, Patrícia A Serra, Nuno Gil

|Jun 28, 2024
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka

|May 21, 2024
RE: Reply to Rio-Vilariño and colleagues' article and misconception about YAP1 Ser 397 phosphorylation function.

Rafael Rosell

Pageof 5

Frequent Collaborators

3 joint publications

Rita Manguinhas

3 joint publications

Sarah Temin

3 joint publications

Paul J Hesketh

3 joint publications

Natasha B Leighl